Please provide your email address to receive an email when new articles are posted on . The impact of food elimination diets on medication previously was unknown. Absolute mean changes in Dysphagia ...

A 3-year interim analysis of the PEDISTAD registry shows dupilumab offers greater improvements in symptoms, quality of life, ...

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to ...

In patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, dupilumab showed sustained efficacy, enabling ...

VANCOUVER, British Columbia -- Treatment with higher-exposure dupilumab (Dupixent) led to sustained improvements in the reduction of peak esophageal intraepithelial eosinophil counts among children ...

This study enhances current understandings of dupilumab use in patients with atopic dermatitis (AD) by showing its real-world effectiveness and safety. Dupilumab is an effective and safe treatment ...

VANCOUVER, Canada — New evidence from the phase 3 EoE KIDS trial supports the safety and efficacy of dupilumab (Dupixent) treatment for children aged 1-11 years with eosinophilic esophagitis (EoE).

They evaluated dupilumab's effects on smell function with 60 patients with nasal polyps who were refractory to intranasal corticosteroids. ATLANTA, GA—The monoclonal antibody dupilumab is associated ...

Patients with AD treated with dupilumab are at a lower risk for otitis media and surgical intervention than those treated with pimecrolimus.

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic ...